#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=The inventors have determined whether sentrin-1 could associate with and covalently modify PML.
1-1	0-3	The	_	_	
1-2	4-13	inventors	_	_	
1-3	14-18	have	_	_	
1-4	19-29	determined	_	_	
1-5	30-37	whether	_	_	
1-6	38-45	sentrin	_	_	
1-7	45-46	-	_	_	
1-8	46-47	1	_	_	
1-9	48-53	could	_	_	
1-10	54-63	associate	_	_	
1-11	64-68	with	_	_	
1-12	69-72	and	_	_	
1-13	73-83	covalently	_	_	
1-14	84-90	modify	_	_	
1-15	91-94	PML	_	_	
1-16	94-95	.	_	_	

#Text=For this purpose, HA-epitope tagged PML (HA-PML) was expressed in COS cells and total cell lysates were analyzed by Western blotting, as previously described (Examples 5 7).
2-1	96-99	For	_	_	
2-2	100-104	this	_	_	
2-3	105-112	purpose	_	_	
2-4	112-113	,	_	_	
2-5	114-124	HA-epitope	_	_	
2-6	125-131	tagged	_	_	
2-7	132-135	PML	_	_	
2-8	136-137	(	_	_	
2-9	137-143	HA-PML	_	_	
2-10	143-144	)	_	_	
2-11	145-148	was	_	_	
2-12	149-158	expressed	_	_	
2-13	159-161	in	_	_	
2-14	162-165	COS	_	_	
2-15	166-171	cells	_	_	
2-16	172-175	and	_	_	
2-17	176-181	total	_	_	
2-18	182-186	cell	_	_	
2-19	187-194	lysates	_	_	
2-20	195-199	were	_	_	
2-21	200-208	analyzed	_	_	
2-22	209-211	by	_	_	
2-23	212-219	Western	_	_	
2-24	220-228	blotting	_	_	
2-25	228-229	,	_	_	
2-26	230-232	as	_	_	
2-27	233-243	previously	_	_	
2-28	244-253	described	_	_	
2-29	254-255	(	_	_	
2-30	255-263	Examples	_	_	
2-31	264-265	5	_	_	
2-32	266-267	7	_	_	
2-33	267-268	)	_	_	
2-34	268-269	.	_	_	

#Text=Three different antibodies were employed in this analysis.
3-1	270-275	Three	_	_	
3-2	276-285	different	_	_	
3-3	286-296	antibodies	_	_	
3-4	297-301	were	_	_	
3-5	302-310	employed	_	_	
3-6	311-313	in	_	_	
3-7	314-318	this	_	_	
3-8	319-327	analysis	_	_	
3-9	327-328	.	_	_	

#Text=As shown in FIG. 11A, a mouse anti-PML monoclonal antibody detected the 70 kDa PML (arrowhead) and a 90 kDa band (lane 2).
4-1	329-331	As	_	_	
4-2	332-337	shown	_	_	
4-3	338-340	in	_	_	
4-4	341-344	FIG	_	_	
4-5	344-345	.	_	_	
4-6	346-349	11A	_	_	
4-7	349-350	,	_	_	
4-8	351-352	a	_	_	
4-9	353-358	mouse	_	_	
4-10	359-367	anti-PML	_	_	
4-11	368-378	monoclonal	_	_	
4-12	379-387	antibody	_	_	
4-13	388-396	detected	_	_	
4-14	397-400	the	_	_	
4-15	401-403	70	_	_	
4-16	404-407	kDa	_	_	
4-17	408-411	PML	_	_	
4-18	412-413	(	_	_	
4-19	413-422	arrowhead	_	_	
4-20	422-423	)	_	_	
4-21	424-427	and	_	_	
4-22	428-429	a	_	_	
4-23	430-432	90	_	_	
4-24	433-436	kDa	_	_	
4-25	437-441	band	_	_	
4-26	442-443	(	_	_	
4-27	443-447	lane	_	_	
4-28	448-449	2	_	_	
4-29	449-450	)	_	_	
4-30	450-451	.	_	_	

#Text=A rabbit anti-PML antiserum detected both the 70 kDa and 90 kDa band (lane 4).
5-1	452-453	A	_	_	
5-2	454-460	rabbit	_	_	
5-3	461-469	anti-PML	_	_	
5-4	470-479	antiserum	_	_	
5-5	480-488	detected	_	_	
5-6	489-493	both	_	_	
5-7	494-497	the	_	_	
5-8	498-500	70	_	_	
5-9	501-504	kDa	_	_	
5-10	505-508	and	_	_	
5-11	509-511	90	_	_	
5-12	512-515	kDa	_	_	
5-13	516-520	band	_	_	
5-14	521-522	(	_	_	
5-15	522-526	lane	_	_	
5-16	527-528	4	_	_	
5-17	528-529	)	_	_	
5-18	529-530	.	_	_	

#Text=There is also a weak higher molecular weight band in the lysate and several lower molecular weight bands, which are most likely degradation products of PML (lane 4).
6-1	531-536	There	_	_	
6-2	537-539	is	_	_	
6-3	540-544	also	_	_	
6-4	545-546	a	_	_	
6-5	547-551	weak	_	_	
6-6	552-558	higher	_	_	
6-7	559-568	molecular	_	_	
6-8	569-575	weight	_	_	
6-9	576-580	band	_	_	
6-10	581-583	in	_	_	
6-11	584-587	the	_	_	
6-12	588-594	lysate	_	_	
6-13	595-598	and	_	_	
6-14	599-606	several	_	_	
6-15	607-612	lower	_	_	
6-16	613-622	molecular	_	_	
6-17	623-629	weight	_	_	
6-18	630-635	bands	_	_	
6-19	635-636	,	_	_	
6-20	637-642	which	_	_	
6-21	643-646	are	_	_	
6-22	647-651	most	_	_	
6-23	652-658	likely	_	_	
6-24	659-670	degradation	_	_	
6-25	671-679	products	_	_	
6-26	680-682	of	_	_	
6-27	683-686	PML	_	_	
6-28	687-688	(	_	_	
6-29	688-692	lane	_	_	
6-30	693-694	4	_	_	
6-31	694-695	)	_	_	
6-32	695-696	.	_	_	

#Text=A highly sensitive anti-HA monoclonal antibody detected several bands higher than 70 kDa (lane 6).
7-1	697-698	A	_	_	
7-2	699-705	highly	_	_	
7-3	706-715	sensitive	_	_	
7-4	716-723	anti-HA	_	_	
7-5	724-734	monoclonal	_	_	
7-6	735-743	antibody	_	_	
7-7	744-752	detected	_	_	
7-8	753-760	several	_	_	
7-9	761-766	bands	_	_	
7-10	767-773	higher	_	_	
7-11	774-778	than	_	_	
7-12	779-781	70	_	_	
7-13	782-785	kDa	_	_	
7-14	786-787	(	_	_	
7-15	787-791	lane	_	_	
7-16	792-793	6	_	_	
7-17	793-794	)	_	_	
7-18	794-795	.	_	_	

#Text=Since the predicted molecular weight of PML is only 70 kDa, the presence of these higher molecular weight bands suggest that PML could either migrate aberrantly or could be modified by other molecules, such as sentrin-1 or ubiquitin.
8-1	796-801	Since	_	_	
8-2	802-805	the	_	_	
8-3	806-815	predicted	_	_	
8-4	816-825	molecular	_	_	
8-5	826-832	weight	_	_	
8-6	833-835	of	_	_	
8-7	836-839	PML	_	_	
8-8	840-842	is	_	_	
8-9	843-847	only	_	_	
8-10	848-850	70	_	_	
8-11	851-854	kDa	_	_	
8-12	854-855	,	_	_	
8-13	856-859	the	_	_	
8-14	860-868	presence	_	_	
8-15	869-871	of	_	_	
8-16	872-877	these	_	_	
8-17	878-884	higher	_	_	
8-18	885-894	molecular	_	_	
8-19	895-901	weight	_	_	
8-20	902-907	bands	_	_	
8-21	908-915	suggest	_	_	
8-22	916-920	that	_	_	
8-23	921-924	PML	_	_	
8-24	925-930	could	_	_	
8-25	931-937	either	_	_	
8-26	938-945	migrate	_	_	
8-27	946-956	aberrantly	_	_	
8-28	957-959	or	_	_	
8-29	960-965	could	_	_	
8-30	966-968	be	_	_	
8-31	969-977	modified	_	_	
8-32	978-980	by	_	_	
8-33	981-986	other	_	_	
8-34	987-996	molecules	_	_	
8-35	996-997	,	_	_	
8-36	998-1002	such	_	_	
8-37	1003-1005	as	_	_	
8-38	1006-1013	sentrin	_	_	
8-39	1013-1014	-	_	_	
8-40	1014-1015	1	_	_	
8-41	1016-1018	or	_	_	
8-42	1019-1028	ubiquitin	_	_	
8-43	1028-1029	.	_	_	

#Text=Next, an immunoprecipitation study was performed with COS cell lysates expressing HA-PML, as previously described (Examples 5 7) (FIG. 11B).
9-1	1030-1034	Next	_	_	
9-2	1034-1035	,	_	_	
9-3	1036-1038	an	_	_	
9-4	1039-1058	immunoprecipitation	_	_	
9-5	1059-1064	study	_	_	
9-6	1065-1068	was	_	_	
9-7	1069-1078	performed	_	_	
9-8	1079-1083	with	_	_	
9-9	1084-1087	COS	_	_	
9-10	1088-1092	cell	_	_	
9-11	1093-1100	lysates	_	_	
9-12	1101-1111	expressing	_	_	
9-13	1112-1118	HA-PML	_	_	
9-14	1118-1119	,	_	_	
9-15	1120-1122	as	_	_	
9-16	1123-1133	previously	_	_	
9-17	1134-1143	described	_	_	
9-18	1144-1145	(	_	_	
9-19	1145-1153	Examples	_	_	
9-20	1154-1155	5	_	_	
9-21	1156-1157	7	_	_	
9-22	1157-1158	)	_	_	
9-23	1159-1160	(	_	_	
9-24	1160-1163	FIG	_	_	
9-25	1163-1164	.	_	_	
9-26	1165-1168	11B	_	_	
9-27	1168-1169	)	_	_	
9-28	1169-1170	.	_	_	

#Text=Two different anti-HA monoclonal antibodies were employed in this study to detect HA-PML and its derivatives.
10-1	1171-1174	Two	_	_	
10-2	1175-1184	different	_	_	
10-3	1185-1192	anti-HA	_	_	
10-4	1193-1203	monoclonal	_	_	
10-5	1204-1214	antibodies	_	_	
10-6	1215-1219	were	_	_	
10-7	1220-1228	employed	_	_	
10-8	1229-1231	in	_	_	
10-9	1232-1236	this	_	_	
10-10	1237-1242	study	_	_	
10-11	1243-1245	to	_	_	
10-12	1246-1252	detect	_	_	
10-13	1253-1259	HA-PML	_	_	
10-14	1260-1263	and	_	_	
10-15	1264-1267	its	_	_	
10-16	1268-1279	derivatives	_	_	
10-17	1279-1280	.	_	_	

#Text=The total cell lysates of the transfected COS cells contained the 70 kDa unmodified HA-PML and a series of higher molecular weight bands (lane 2).
11-1	1281-1284	The	_	_	
11-2	1285-1290	total	_	_	
11-3	1291-1295	cell	_	_	
11-4	1296-1303	lysates	_	_	
11-5	1304-1306	of	_	_	
11-6	1307-1310	the	_	_	
11-7	1311-1322	transfected	_	_	
11-8	1323-1326	COS	_	_	
11-9	1327-1332	cells	_	_	
11-10	1333-1342	contained	_	_	
11-11	1343-1346	the	_	_	
11-12	1347-1349	70	_	_	
11-13	1350-1353	kDa	_	_	
11-14	1354-1364	unmodified	_	_	
11-15	1365-1371	HA-PML	_	_	
11-16	1372-1375	and	_	_	
11-17	1376-1377	a	_	_	
11-18	1378-1384	series	_	_	
11-19	1385-1387	of	_	_	
11-20	1388-1394	higher	_	_	
11-21	1395-1404	molecular	_	_	
11-22	1405-1411	weight	_	_	
11-23	1412-1417	bands	_	_	
11-24	1418-1419	(	_	_	
11-25	1419-1423	lane	_	_	
11-26	1424-1425	2	_	_	
11-27	1425-1426	)	_	_	
11-28	1426-1427	.	_	_	

#Text=As shown in lane 4, anti-FADD antiserum (Kamitani et al., 1997c) did not precipitate any proteins from the lysate.
12-1	1428-1430	As	_	_	
12-2	1431-1436	shown	_	_	
12-3	1437-1439	in	_	_	
12-4	1440-1444	lane	_	_	
12-5	1445-1446	4	_	_	
12-6	1446-1447	,	_	_	
12-7	1448-1457	anti-FADD	_	_	
12-8	1458-1467	antiserum	_	_	
12-9	1468-1469	(	_	_	
12-10	1469-1477	Kamitani	_	_	
12-11	1478-1480	et	_	_	
12-12	1481-1483	al	_	_	
12-13	1483-1484	.	_	_	
12-14	1484-1485	,	_	_	
12-15	1486-1491	1997c	_	_	
12-16	1491-1492	)	_	_	
12-17	1493-1496	did	_	_	
12-18	1497-1500	not	_	_	
12-19	1501-1512	precipitate	_	_	
12-20	1513-1516	any	_	_	
12-21	1517-1525	proteins	_	_	
12-22	1526-1530	from	_	_	
12-23	1531-1534	the	_	_	
12-24	1535-1541	lysate	_	_	
12-25	1541-1542	.	_	_	

#Text=In contrast, immunoprecipitation with anti-sentrin-1 antiserum (Kamitani et al., 1997a) precipitated two proteins that were approximately 70 and 90 kDa (lane 6).
13-1	1543-1545	In	_	_	
13-2	1546-1554	contrast	_	_	
13-3	1554-1555	,	_	_	
13-4	1556-1575	immunoprecipitation	_	_	
13-5	1576-1580	with	_	_	
13-6	1581-1593	anti-sentrin	_	_	
13-7	1593-1594	-	_	_	
13-8	1594-1595	1	_	_	
13-9	1596-1605	antiserum	_	_	
13-10	1606-1607	(	_	_	
13-11	1607-1615	Kamitani	_	_	
13-12	1616-1618	et	_	_	
13-13	1619-1621	al	_	_	
13-14	1621-1622	.	_	_	
13-15	1622-1623	,	_	_	
13-16	1624-1629	1997a	_	_	
13-17	1629-1630	)	_	_	
13-18	1631-1643	precipitated	_	_	
13-19	1644-1647	two	_	_	
13-20	1648-1656	proteins	_	_	
13-21	1657-1661	that	_	_	
13-22	1662-1666	were	_	_	
13-23	1667-1680	approximately	_	_	
13-24	1681-1683	70	_	_	
13-25	1684-1687	and	_	_	
13-26	1688-1690	90	_	_	
13-27	1691-1694	kDa	_	_	
13-28	1695-1696	(	_	_	
13-29	1696-1700	lane	_	_	
13-30	1701-1702	6	_	_	
13-31	1702-1703	)	_	_	
13-32	1703-1704	.	_	_	

#Text=These results suggest that HA-PML could be modified by sentrin-1.
14-1	1705-1710	These	_	_	
14-2	1711-1718	results	_	_	
14-3	1719-1726	suggest	_	_	
14-4	1727-1731	that	_	_	
14-5	1732-1738	HA-PML	_	_	
14-6	1739-1744	could	_	_	
14-7	1745-1747	be	_	_	
14-8	1748-1756	modified	_	_	
14-9	1757-1759	by	_	_	
14-10	1760-1767	sentrin	_	_	
14-11	1767-1768	-	_	_	
14-12	1768-1769	1	_	_	
14-13	1769-1770	.	_	_	

#Text=However, the molecular weight of the precipitate does not match the modification pattern seen in FIG. 11A.
15-1	1771-1778	However	*[1]	17-3[2_1]	
15-2	1778-1779	,	*[1]	_	
15-3	1780-1783	the	*[1]	_	
15-4	1784-1793	molecular	*[1]	_	
15-5	1794-1800	weight	*[1]	_	
15-6	1801-1803	of	*[1]	_	
15-7	1804-1807	the	*[1]	_	
15-8	1808-1819	precipitate	*[1]	_	
15-9	1820-1824	does	*[1]	_	
15-10	1825-1828	not	*[1]	_	
15-11	1829-1834	match	*[1]	_	
15-12	1835-1838	the	*[1]	_	
15-13	1839-1851	modification	*[1]	_	
15-14	1852-1859	pattern	*[1]	_	
15-15	1860-1864	seen	*[1]	_	
15-16	1865-1867	in	*[1]	_	
15-17	1868-1871	FIG	*[1]	_	
15-18	1871-1872	.	*[1]	_	
15-19	1873-1876	11A	*[1]	_	
15-20	1876-1877	.	*[1]	_	

#Text=This is most likely due to protein degradation or de-sentrinization during immunoprecipitation.
16-1	1878-1882	This	_	_	
16-2	1883-1885	is	_	_	
16-3	1886-1890	most	_	_	
16-4	1891-1897	likely	_	_	
16-5	1898-1901	due	_	_	
16-6	1902-1904	to	_	_	
16-7	1905-1912	protein	_	_	
16-8	1913-1924	degradation	_	_	
16-9	1925-1927	or	_	_	
16-10	1928-1945	de-sentrinization	_	_	
16-11	1946-1952	during	_	_	
16-12	1953-1972	immunoprecipitation	_	_	
16-13	1972-1973	.	_	_	

#Text=To circumvent this problem, a different system was employed, as described in the inventors' recent report demonstrating the conjugation of sentrin-1 to RanGAP1.
17-1	1974-1976	To	_	_	
17-2	1977-1987	circumvent	_	_	
17-3	1988-1992	this	*[2]	_	
17-4	1993-2000	problem	*[2]	_	
17-5	2000-2001	,	_	_	
17-6	2002-2003	a	_	_	
17-7	2004-2013	different	_	_	
17-8	2014-2020	system	_	_	
17-9	2021-2024	was	_	_	
17-10	2025-2033	employed	_	_	
17-11	2033-2034	,	_	_	
17-12	2035-2037	as	_	_	
17-13	2038-2047	described	_	_	
17-14	2048-2050	in	_	_	
17-15	2051-2054	the	_	_	
17-16	2055-2064	inventors	_	_	
17-17	2064-2065	'	_	_	
17-18	2066-2072	recent	_	_	
17-19	2073-2079	report	_	_	
17-20	2080-2093	demonstrating	_	_	
17-21	2094-2097	the	_	_	
17-22	2098-2109	conjugation	_	_	
17-23	2110-2112	of	_	_	
17-24	2113-2120	sentrin	_	_	
17-25	2120-2121	-	_	_	
17-26	2121-2122	1	_	_	
17-27	2123-2125	to	_	_	
17-28	2126-2133	RanGAP1	_	_	
17-29	2133-2134	.	_	_	

#Text=Here, PML was tagged with RH epitope (RGSHHHHHH) (SEQ ID NO:7) at the C-terminus and expressed in COS cells.
18-1	2135-2139	Here	_	_	
18-2	2139-2140	,	_	_	
18-3	2141-2144	PML	_	_	
18-4	2145-2148	was	_	_	
18-5	2149-2155	tagged	_	_	
18-6	2156-2160	with	_	_	
18-7	2161-2163	RH	_	_	
18-8	2164-2171	epitope	_	_	
18-9	2172-2173	(	_	_	
18-10	2173-2182	RGSHHHHHH	_	_	
18-11	2182-2183	)	_	_	
18-12	2184-2185	(	_	_	
18-13	2185-2188	SEQ	_	_	
18-14	2189-2191	ID	_	_	
18-15	2192-2194	NO	_	_	
18-16	2194-2195	:	_	_	
18-17	2195-2196	7	_	_	
18-18	2196-2197	)	_	_	
18-19	2198-2200	at	_	_	
18-20	2201-2204	the	_	_	
18-21	2205-2215	C-terminus	_	_	
18-22	2216-2219	and	_	_	
18-23	2220-2229	expressed	_	_	
18-24	2230-2232	in	_	_	
18-25	2233-2236	COS	_	_	
18-26	2237-2242	cells	_	_	
18-27	2242-2243	.	_	_	

#Text=Transfected cells were lysed with 6 M Guanidine HCl to denature proteins in the lysate and to prevent any non-specific proteolysis or de-sentrinization.
19-1	2244-2255	Transfected	_	_	
19-2	2256-2261	cells	_	_	
19-3	2262-2266	were	_	_	
19-4	2267-2272	lysed	_	_	
19-5	2273-2277	with	_	_	
19-6	2278-2279	6	_	_	
19-7	2280-2281	M	_	_	
19-8	2282-2291	Guanidine	_	_	
19-9	2292-2295	HCl	_	_	
19-10	2296-2298	to	_	_	
19-11	2299-2307	denature	_	_	
19-12	2308-2316	proteins	_	_	
19-13	2317-2319	in	_	_	
19-14	2320-2323	the	_	_	
19-15	2324-2330	lysate	_	_	
19-16	2331-2334	and	_	_	
19-17	2335-2337	to	_	_	
19-18	2338-2345	prevent	_	_	
19-19	2346-2349	any	_	_	
19-20	2350-2362	non-specific	_	_	
19-21	2363-2374	proteolysis	_	_	
19-22	2375-2377	or	_	_	
19-23	2378-2395	de-sentrinization	_	_	
19-24	2395-2396	.	_	_	

#Text=RH-tagged PML (PML-RH) was then precipitated with nickel-charged beads and was immunoblotted with either anti-sentrin-1 antiserum or with anti-RH monoclonal antibody.
20-1	2397-2406	RH-tagged	_	_	
20-2	2407-2410	PML	_	_	
20-3	2411-2412	(	_	_	
20-4	2412-2418	PML-RH	_	_	
20-5	2418-2419	)	_	_	
20-6	2420-2423	was	_	_	
20-7	2424-2428	then	_	_	
20-8	2429-2441	precipitated	_	_	
20-9	2442-2446	with	_	_	
20-10	2447-2461	nickel-charged	_	_	
20-11	2462-2467	beads	_	_	
20-12	2468-2471	and	_	_	
20-13	2472-2475	was	_	_	
20-14	2476-2489	immunoblotted	_	_	
20-15	2490-2494	with	_	_	
20-16	2495-2501	either	_	_	
20-17	2502-2514	anti-sentrin	_	_	
20-18	2514-2515	-	_	_	
20-19	2515-2516	1	_	_	
20-20	2517-2526	antiserum	_	_	
20-21	2527-2529	or	_	_	
20-22	2530-2534	with	_	_	
20-23	2535-2542	anti-RH	_	_	
20-24	2543-2553	monoclonal	_	_	
20-25	2554-2562	antibody	_	_	
20-26	2562-2563	.	_	_	

#Text=As shown in FIG. 11C, 3 distinct bands were identified in the anti-sentrin-1 and anti-RH lanes (lanes 2, 4).
21-1	2564-2566	As	_	_	
21-2	2567-2572	shown	_	_	
21-3	2573-2575	in	_	_	
21-4	2576-2579	FIG	_	_	
21-5	2579-2580	.	_	_	
21-6	2581-2584	11C	_	_	
21-7	2584-2585	,	_	_	
21-8	2586-2587	3	_	_	
21-9	2588-2596	distinct	_	_	
21-10	2597-2602	bands	_	_	
21-11	2603-2607	were	_	_	
21-12	2608-2618	identified	_	_	
21-13	2619-2621	in	_	_	
21-14	2622-2625	the	_	_	
21-15	2626-2638	anti-sentrin	_	_	
21-16	2638-2639	-	_	_	
21-17	2639-2640	1	_	_	
21-18	2641-2644	and	_	_	
21-19	2645-2652	anti-RH	_	_	
21-20	2653-2658	lanes	_	_	
21-21	2659-2660	(	_	_	
21-22	2660-2665	lanes	_	_	
21-23	2666-2667	2	_	_	
21-24	2667-2668	,	_	_	
21-25	2669-2670	4	_	_	
21-26	2670-2671	)	_	_	
21-27	2671-2672	.	_	_	

#Text=As a control, HA-PML could not be precipitated by nickel-charged beads and could not be detected with either anti-sentrin-1 antiserum or anti-RH antibody (lanes 1, 3).
22-1	2673-2675	As	_	_	
22-2	2676-2677	a	_	_	
22-3	2678-2685	control	_	_	
22-4	2685-2686	,	_	_	
22-5	2687-2693	HA-PML	_	_	
22-6	2694-2699	could	_	_	
22-7	2700-2703	not	_	_	
22-8	2704-2706	be	_	_	
22-9	2707-2719	precipitated	_	_	
22-10	2720-2722	by	_	_	
22-11	2723-2737	nickel-charged	_	_	
22-12	2738-2743	beads	_	_	
22-13	2744-2747	and	_	_	
22-14	2748-2753	could	_	_	
22-15	2754-2757	not	_	_	
22-16	2758-2760	be	_	_	
22-17	2761-2769	detected	_	_	
22-18	2770-2774	with	_	_	
22-19	2775-2781	either	_	_	
22-20	2782-2794	anti-sentrin	_	_	
22-21	2794-2795	-	_	_	
22-22	2795-2796	1	_	_	
22-23	2797-2806	antiserum	_	_	
22-24	2807-2809	or	_	_	
22-25	2810-2817	anti-RH	_	_	
22-26	2818-2826	antibody	_	_	
22-27	2827-2828	(	_	_	
22-28	2828-2833	lanes	_	_	
22-29	2834-2835	1	_	_	
22-30	2835-2836	,	_	_	
22-31	2837-2838	3	_	_	
22-32	2838-2839	)	_	_	
22-33	2839-2840	.	_	_	

#Text=These studies suggest that PML is covalently modified by sentrin-1 at multiple sites.
23-1	2841-2846	These	_	_	
23-2	2847-2854	studies	_	_	
23-3	2855-2862	suggest	_	_	
23-4	2863-2867	that	_	_	
23-5	2868-2871	PML	_	_	
23-6	2872-2874	is	_	_	
23-7	2875-2885	covalently	_	_	
23-8	2886-2894	modified	_	_	
23-9	2895-2897	by	_	_	
23-10	2898-2905	sentrin	_	_	
23-11	2905-2906	-	_	_	
23-12	2906-2907	1	_	_	
23-13	2908-2910	at	_	_	
23-14	2911-2919	multiple	_	_	
23-15	2920-2925	sites	_	_	
23-16	2925-2926	.	_	_	

#Text=The inventors do not favor the possibility of modification at the single site by sentrin-1 multimers because sentrin-1 does not contain the conserved Lys48 equivalent required for multimer formation (Hershko and Ciechanover, 1992) (see FIG. 12).
24-1	2927-2930	The	_	_	
24-2	2931-2940	inventors	_	_	
24-3	2941-2943	do	_	_	
24-4	2944-2947	not	_	_	
24-5	2948-2953	favor	_	_	
24-6	2954-2957	the	_	_	
24-7	2958-2969	possibility	_	_	
24-8	2970-2972	of	_	_	
24-9	2973-2985	modification	_	_	
24-10	2986-2988	at	_	_	
24-11	2989-2992	the	_	_	
24-12	2993-2999	single	_	_	
24-13	3000-3004	site	_	_	
24-14	3005-3007	by	_	_	
24-15	3008-3015	sentrin	_	_	
24-16	3015-3016	-	_	_	
24-17	3016-3017	1	_	_	
24-18	3018-3027	multimers	_	_	
24-19	3028-3035	because	_	_	
24-20	3036-3043	sentrin	_	_	
24-21	3043-3044	-	_	_	
24-22	3044-3045	1	_	_	
24-23	3046-3050	does	_	_	
24-24	3051-3054	not	_	_	
24-25	3055-3062	contain	_	_	
24-26	3063-3066	the	_	_	
24-27	3067-3076	conserved	_	_	
24-28	3077-3082	Lys48	_	_	
24-29	3083-3093	equivalent	_	_	
24-30	3094-3102	required	_	_	
24-31	3103-3106	for	_	_	
24-32	3107-3115	multimer	_	_	
24-33	3116-3125	formation	_	_	
24-34	3126-3127	(	_	_	
24-35	3127-3134	Hershko	_	_	
24-36	3135-3138	and	_	_	
24-37	3139-3150	Ciechanover	_	_	
24-38	3150-3151	,	_	_	
24-39	3152-3156	1992	_	_	
24-40	3156-3157	)	_	_	
24-41	3158-3159	(	_	_	
24-42	3159-3162	see	_	_	
24-43	3163-3166	FIG	_	_	
24-44	3166-3167	.	_	_	
24-45	3168-3170	12	_	_	
24-46	3170-3171	)	_	_	
24-47	3171-3172	.	_	_	

#Text=This notion is further supported by the observation that RanGAP1 is modified by a single molecule of sentrin-1/GMP1/SUMO1 (Kamitani et al., 1997b; Mahajan et al., 1997; Matunis et al., 1996).
25-1	3173-3177	This	_	_	
25-2	3178-3184	notion	_	_	
25-3	3185-3187	is	_	_	
25-4	3188-3195	further	_	_	
25-5	3196-3205	supported	_	_	
25-6	3206-3208	by	_	_	
25-7	3209-3212	the	_	_	
25-8	3213-3224	observation	_	_	
25-9	3225-3229	that	_	_	
25-10	3230-3237	RanGAP1	_	_	
25-11	3238-3240	is	_	_	
25-12	3241-3249	modified	_	_	
25-13	3250-3252	by	_	_	
25-14	3253-3254	a	_	_	
25-15	3255-3261	single	_	_	
25-16	3262-3270	molecule	_	_	
25-17	3271-3273	of	_	_	
25-18	3274-3281	sentrin	_	_	
25-19	3281-3282	-	_	_	
25-20	3282-3283	1	_	_	
25-21	3283-3284	/	_	_	
25-22	3284-3288	GMP1	_	_	
25-23	3288-3289	/	_	_	
25-24	3289-3294	SUMO1	_	_	
25-25	3295-3296	(	_	_	
25-26	3296-3304	Kamitani	_	_	
25-27	3305-3307	et	_	_	
25-28	3308-3310	al	_	_	
25-29	3310-3311	.	_	_	
25-30	3311-3312	,	_	_	
25-31	3313-3318	1997b	_	_	
25-32	3318-3319	;	_	_	
25-33	3320-3327	Mahajan	_	_	
25-34	3328-3330	et	_	_	
25-35	3331-3333	al	_	_	
25-36	3333-3334	.	_	_	
25-37	3334-3335	,	_	_	
25-38	3336-3340	1997	_	_	
25-39	3340-3341	;	_	_	
25-40	3342-3349	Matunis	_	_	
25-41	3350-3352	et	_	_	
25-42	3353-3355	al	_	_	
25-43	3355-3356	.	_	_	
25-44	3356-3357	,	_	_	
25-45	3358-3362	1996	_	_	
25-46	3362-3363	)	_	_	
25-47	3363-3364	.	_	_	

#Text=Sentrin-1 belongs to a family of ubiquitin-like proteins (see FIG. 12).
26-1	3365-3372	Sentrin	_	_	
26-2	3372-3373	-	_	_	
26-3	3373-3374	1	_	_	
26-4	3375-3382	belongs	_	_	
26-5	3383-3385	to	_	_	
26-6	3386-3387	a	_	_	
26-7	3388-3394	family	_	_	
26-8	3395-3397	of	_	_	
26-9	3398-3412	ubiquitin-like	_	_	
26-10	3413-3421	proteins	_	_	
26-11	3422-3423	(	_	_	
26-12	3423-3426	see	_	_	
26-13	3427-3430	FIG	_	_	
26-14	3430-3431	.	_	_	
26-15	3432-3434	12	_	_	
26-16	3434-3435	)	_	_	
26-17	3435-3436	.	_	_	

#Text=Sentrin homologues have been reported from A. thaliana to H. sapiens, suggesting that sentrin-1 is an evolutionary conserved protein that may perform unique functions in cellular metabolism.
27-1	3437-3444	Sentrin	_	_	
27-2	3445-3455	homologues	_	_	
27-3	3456-3460	have	_	_	
27-4	3461-3465	been	_	_	
27-5	3466-3474	reported	_	_	
27-6	3475-3479	from	_	_	
27-7	3480-3481	A	_	_	
27-8	3481-3482	.	_	_	
27-9	3483-3491	thaliana	_	_	
27-10	3492-3494	to	_	_	
27-11	3495-3496	H	_	_	
27-12	3496-3497	.	_	_	
27-13	3498-3505	sapiens	_	_	
27-14	3505-3506	,	_	_	
27-15	3507-3517	suggesting	_	_	
27-16	3518-3522	that	_	_	
27-17	3523-3530	sentrin	_	_	
27-18	3530-3531	-	_	_	
27-19	3531-3532	1	_	_	
27-20	3533-3535	is	_	_	
27-21	3536-3538	an	_	_	
27-22	3539-3551	evolutionary	_	_	
27-23	3552-3561	conserved	_	_	
27-24	3562-3569	protein	_	_	
27-25	3570-3574	that	_	_	
27-26	3575-3578	may	_	_	
27-27	3579-3586	perform	_	_	
27-28	3587-3593	unique	_	_	
27-29	3594-3603	functions	_	_	
27-30	3604-3606	in	_	_	
27-31	3607-3615	cellular	_	_	
27-32	3616-3626	metabolism	_	_	
27-33	3626-3627	.	_	_	

#Text=Further analysis of the database revealed two additional human cDNA sequences that are highly homologous to sentrin-1 (Mannen et al., 1996; Lapenta et al., 1997).
28-1	3628-3635	Further	_	_	
28-2	3636-3644	analysis	_	_	
28-3	3645-3647	of	_	_	
28-4	3648-3651	the	_	_	
28-5	3652-3660	database	_	_	
28-6	3661-3669	revealed	_	_	
28-7	3670-3673	two	_	_	
28-8	3674-3684	additional	_	_	
28-9	3685-3690	human	_	_	
28-10	3691-3695	cDNA	_	_	
28-11	3696-3705	sequences	_	_	
28-12	3706-3710	that	_	_	
28-13	3711-3714	are	_	_	
28-14	3715-3721	highly	_	_	
28-15	3722-3732	homologous	_	_	
28-16	3733-3735	to	_	_	
28-17	3736-3743	sentrin	_	_	
28-18	3743-3744	-	_	_	
28-19	3744-3745	1	_	_	
28-20	3746-3747	(	_	_	
28-21	3747-3753	Mannen	_	_	
28-22	3754-3756	et	_	_	
28-23	3757-3759	al	_	_	
28-24	3759-3760	.	_	_	
28-25	3760-3761	,	_	_	
28-26	3762-3766	1996	_	_	
28-27	3766-3767	;	_	_	
28-28	3768-3775	Lapenta	_	_	
28-29	3776-3778	et	_	_	
28-30	3779-3781	al	_	_	
28-31	3781-3782	.	_	_	
28-32	3782-3783	,	_	_	
28-33	3784-3788	1997	_	_	
28-34	3788-3789	)	_	_	
28-35	3789-3790	.	_	_	

#Text=This is of interest because there is only one sentrin homologue reported for all of the non-mammalian genera and species.
29-1	3791-3795	This	_	_	
29-2	3796-3798	is	_	_	
29-3	3799-3801	of	_	_	
29-4	3802-3810	interest	_	_	
29-5	3811-3818	because	_	_	
29-6	3819-3824	there	_	_	
29-7	3825-3827	is	_	_	
29-8	3828-3832	only	_	_	
29-9	3833-3836	one	_	_	
29-10	3837-3844	sentrin	_	_	
29-11	3845-3854	homologue	_	_	
29-12	3855-3863	reported	_	_	
29-13	3864-3867	for	_	_	
29-14	3868-3871	all	_	_	
29-15	3872-3874	of	_	_	
29-16	3875-3878	the	_	_	
29-17	3879-3892	non-mammalian	_	_	
29-18	3893-3899	genera	_	_	
29-19	3900-3903	and	_	_	
29-20	3904-3911	species	_	_	
29-21	3911-3912	.	_	_	

#Text=While original publications by the inventors referred to the protein as "sentrin", the inventors have now renamed the protein "sentrin-1" and the other two sequences as sentrin-2 (T08096/X99585) and sentrin-3 (X99584).
30-1	3913-3918	While	_	_	
30-2	3919-3927	original	_	_	
30-3	3928-3940	publications	_	_	
30-4	3941-3943	by	_	_	
30-5	3944-3947	the	_	_	
30-6	3948-3957	inventors	_	_	
30-7	3958-3966	referred	_	_	
30-8	3967-3969	to	_	_	
30-9	3970-3973	the	_	_	
30-10	3974-3981	protein	_	_	
30-11	3982-3984	as	_	_	
30-12	3985-3986	"	_	_	
30-13	3986-3993	sentrin	_	_	
30-14	3993-3994	"	_	_	
30-15	3994-3995	,	_	_	
30-16	3996-3999	the	_	_	
30-17	4000-4009	inventors	_	_	
30-18	4010-4014	have	_	_	
30-19	4015-4018	now	_	_	
30-20	4019-4026	renamed	_	_	
30-21	4027-4030	the	_	_	
30-22	4031-4038	protein	_	_	
30-23	4039-4040	"	_	_	
30-24	4040-4047	sentrin	_	_	
30-25	4047-4048	-	_	_	
30-26	4048-4049	1	_	_	
30-27	4049-4050	"	_	_	
30-28	4051-4054	and	_	_	
30-29	4055-4058	the	_	_	
30-30	4059-4064	other	_	_	
30-31	4065-4068	two	_	_	
30-32	4069-4078	sequences	_	_	
30-33	4079-4081	as	_	_	
30-34	4082-4089	sentrin	_	_	
30-35	4089-4090	-	_	_	
30-36	4090-4091	2	_	_	
30-37	4092-4093	(	_	_	
30-38	4093-4099	T08096	_	_	
30-39	4099-4100	/	_	_	
30-40	4100-4106	X99585	_	_	
30-41	4106-4107	)	_	_	
30-42	4108-4111	and	_	_	
30-43	4112-4119	sentrin	_	_	
30-44	4119-4120	-	_	_	
30-45	4120-4121	3	_	_	
30-46	4122-4123	(	_	_	
30-47	4123-4129	X99584	_	_	
30-48	4129-4130	)	_	_	
30-49	4130-4131	.	_	_	

#Text=It is not known whether sentrin-2 or sentrin-3 could form covalent conjugates with other proteins.
31-1	4132-4134	It	_	_	
31-2	4135-4137	is	_	_	
31-3	4138-4141	not	_	_	
31-4	4142-4147	known	_	_	
31-5	4148-4155	whether	_	_	
31-6	4156-4163	sentrin	_	_	
31-7	4163-4164	-	_	_	
31-8	4164-4165	2	_	_	
31-9	4166-4168	or	_	_	
31-10	4169-4176	sentrin	_	_	
31-11	4176-4177	-	_	_	
31-12	4177-4178	3	_	_	
31-13	4179-4184	could	_	_	
31-14	4185-4189	form	_	_	
31-15	4190-4198	covalent	_	_	
31-16	4199-4209	conjugates	_	_	
31-17	4210-4214	with	_	_	
31-18	4215-4220	other	_	_	
31-19	4221-4229	proteins	_	_	
31-20	4229-4230	.	_	_	

#Text=Since sentrin-1 could covalently modify PML, it is of interest to determine whether sentrin-2 or sentrin-3 could also be used as PML modifiers.
32-1	4231-4236	Since	_	_	
32-2	4237-4244	sentrin	_	_	
32-3	4244-4245	-	_	_	
32-4	4245-4246	1	_	_	
32-5	4247-4252	could	_	_	
32-6	4253-4263	covalently	_	_	
32-7	4264-4270	modify	_	_	
32-8	4271-4274	PML	_	_	
32-9	4274-4275	,	_	_	
32-10	4276-4278	it	_	_	
32-11	4279-4281	is	_	_	
32-12	4282-4284	of	_	_	
32-13	4285-4293	interest	_	_	
32-14	4294-4296	to	_	_	
32-15	4297-4306	determine	_	_	
32-16	4307-4314	whether	_	_	
32-17	4315-4322	sentrin	_	_	
32-18	4322-4323	-	_	_	
32-19	4323-4324	2	_	_	
32-20	4325-4327	or	_	_	
32-21	4328-4335	sentrin	_	_	
32-22	4335-4336	-	_	_	
32-23	4336-4337	3	_	_	
32-24	4338-4343	could	_	_	
32-25	4344-4348	also	_	_	
32-26	4349-4351	be	_	_	
32-27	4352-4356	used	_	_	
32-28	4357-4359	as	_	_	
32-29	4360-4363	PML	_	_	
32-30	4364-4373	modifiers	_	_	
32-31	4373-4374	.	_	_	

#Text=For this purpose, HA-tag was placed at the N-termini of sentrin-1, sentrin-2, and sentrin-3 and expressed in COS cells as previously described (Kamitani et al., 1997a).
33-1	4375-4378	For	_	_	
33-2	4379-4383	this	_	_	
33-3	4384-4391	purpose	_	_	
33-4	4391-4392	,	_	_	
33-5	4393-4399	HA-tag	_	_	
33-6	4400-4403	was	_	_	
33-7	4404-4410	placed	_	_	
33-8	4411-4413	at	_	_	
33-9	4414-4417	the	_	_	
33-10	4418-4427	N-termini	_	_	
33-11	4428-4430	of	_	_	
33-12	4431-4438	sentrin	_	_	
33-13	4438-4439	-	_	_	
33-14	4439-4440	1	_	_	
33-15	4440-4441	,	_	_	
33-16	4442-4449	sentrin	_	_	
33-17	4449-4450	-	_	_	
33-18	4450-4451	2	_	_	
33-19	4451-4452	,	_	_	
33-20	4453-4456	and	_	_	
33-21	4457-4464	sentrin	_	_	
33-22	4464-4465	-	_	_	
33-23	4465-4466	3	_	_	
33-24	4467-4470	and	_	_	
33-25	4471-4480	expressed	_	_	
33-26	4481-4483	in	_	_	
33-27	4484-4487	COS	_	_	
33-28	4488-4493	cells	_	_	
33-29	4494-4496	as	_	_	
33-30	4497-4507	previously	_	_	
33-31	4508-4517	described	_	_	
33-32	4518-4519	(	_	_	
33-33	4519-4527	Kamitani	_	_	
33-34	4528-4530	et	_	_	
33-35	4531-4533	al	_	_	
33-36	4533-4534	.	_	_	
33-37	4534-4535	,	_	_	
33-38	4536-4541	1997a	_	_	
33-39	4541-4542	)	_	_	
33-40	4542-4543	.	_	_	

#Text=RanGAP1 was used as a positive control because RanGAP1 is covalently modified by sentrin-1 or SUMO-1/GMP1 (Kamitani et al., 1997a; Mahajan et al., 1997; Matunis et al., 1996).
34-1	4544-4551	RanGAP1	_	_	
34-2	4552-4555	was	_	_	
34-3	4556-4560	used	_	_	
34-4	4561-4563	as	_	_	
34-5	4564-4565	a	_	_	
34-6	4566-4574	positive	_	_	
34-7	4575-4582	control	_	_	
34-8	4583-4590	because	_	_	
34-9	4591-4598	RanGAP1	_	_	
34-10	4599-4601	is	_	_	
34-11	4602-4612	covalently	_	_	
34-12	4613-4621	modified	_	_	
34-13	4622-4624	by	_	_	
34-14	4625-4632	sentrin	_	_	
34-15	4632-4633	-	_	_	
34-16	4633-4634	1	_	_	
34-17	4635-4637	or	_	_	
34-18	4638-4642	SUMO	_	_	
34-19	4642-4643	-	_	_	
34-20	4643-4644	1	_	_	
34-21	4644-4645	/	_	_	
34-22	4645-4649	GMP1	_	_	
34-23	4650-4651	(	_	_	
34-24	4651-4659	Kamitani	_	_	
34-25	4660-4662	et	_	_	
34-26	4663-4665	al	_	_	
34-27	4665-4666	.	_	_	
34-28	4666-4667	,	_	_	
34-29	4668-4673	1997a	_	_	
34-30	4673-4674	;	_	_	
34-31	4675-4682	Mahajan	_	_	
34-32	4683-4685	et	_	_	
34-33	4686-4688	al	_	_	
34-34	4688-4689	.	_	_	
34-35	4689-4690	,	_	_	
34-36	4691-4695	1997	_	_	
34-37	4695-4696	;	_	_	
34-38	4697-4704	Matunis	_	_	
34-39	4705-4707	et	_	_	
34-40	4708-4710	al	_	_	
34-41	4710-4711	.	_	_	
34-42	4711-4712	,	_	_	
34-43	4713-4717	1996	_	_	
34-44	4717-4718	)	_	_	
34-45	4718-4719	.	_	_	

#Text=It is not known, however, whether RanGAP1 could be modified by sentrin-2 or sentrin-3.
35-1	4720-4722	It	_	_	
35-2	4723-4725	is	_	_	
35-3	4726-4729	not	_	_	
35-4	4730-4735	known	_	_	
35-5	4735-4736	,	_	_	
35-6	4737-4744	however	_	_	
35-7	4744-4745	,	_	_	
35-8	4746-4753	whether	_	_	
35-9	4754-4761	RanGAP1	_	_	
35-10	4762-4767	could	_	_	
35-11	4768-4770	be	_	_	
35-12	4771-4779	modified	_	_	
35-13	4780-4782	by	_	_	
35-14	4783-4790	sentrin	_	_	
35-15	4790-4791	-	_	_	
35-16	4791-4792	2	_	_	
35-17	4793-4795	or	_	_	
35-18	4796-4803	sentrin	_	_	
35-19	4803-4804	-	_	_	
35-20	4804-4805	3	_	_	
35-21	4805-4806	.	_	_	

#Text=HA-tagged sentrin family members were co-expressed with RH-RanGAP1 in COS cells.
36-1	4807-4816	HA-tagged	_	_	
36-2	4817-4824	sentrin	_	_	
36-3	4825-4831	family	_	_	
36-4	4832-4839	members	_	_	
36-5	4840-4844	were	_	_	
36-6	4845-4857	co-expressed	_	_	
36-7	4858-4862	with	_	_	
36-8	4863-4873	RH-RanGAP1	_	_	
36-9	4874-4876	in	_	_	
36-10	4877-4880	COS	_	_	
36-11	4881-4886	cells	_	_	
36-12	4886-4887	.	_	_	

#Text=Total cell lysates were incubated with nickel-charged beads to precipitate RH-RanGAP1 and its derivatives.
37-1	4888-4893	Total	_	_	
37-2	4894-4898	cell	_	_	
37-3	4899-4906	lysates	_	_	
37-4	4907-4911	were	_	_	
37-5	4912-4921	incubated	_	_	
37-6	4922-4926	with	_	_	
37-7	4927-4941	nickel-charged	_	_	
37-8	4942-4947	beads	_	_	
37-9	4948-4950	to	_	_	
37-10	4951-4962	precipitate	_	_	
37-11	4963-4973	RH-RanGAP1	_	_	
37-12	4974-4977	and	_	_	
37-13	4978-4981	its	_	_	
37-14	4982-4993	derivatives	_	_	
37-15	4993-4994	.	_	_	

#Text=As shown in FIG. 13A, sentrin-1, sentrin-2, or sentrin-3 could covalently modify RanGAP1 (lane 4, 5, 6).
38-1	4995-4997	As	_	_	
38-2	4998-5003	shown	_	_	
38-3	5004-5006	in	_	_	
38-4	5007-5010	FIG	_	_	
38-5	5010-5011	.	_	_	
38-6	5012-5015	13A	_	_	
38-7	5015-5016	,	_	_	
38-8	5017-5024	sentrin	_	_	
38-9	5024-5025	-	_	_	
38-10	5025-5026	1	_	_	
38-11	5026-5027	,	_	_	
38-12	5028-5035	sentrin	_	_	
38-13	5035-5036	-	_	_	
38-14	5036-5037	2	_	_	
38-15	5037-5038	,	_	_	
38-16	5039-5041	or	_	_	
38-17	5042-5049	sentrin	_	_	
38-18	5049-5050	-	_	_	
38-19	5050-5051	3	_	_	
38-20	5052-5057	could	_	_	
38-21	5058-5068	covalently	_	_	
38-22	5069-5075	modify	_	_	
38-23	5076-5083	RanGAP1	_	_	
38-24	5084-5085	(	_	_	
38-25	5085-5089	lane	_	_	
38-26	5090-5091	4	_	_	
38-27	5091-5092	,	_	_	
38-28	5093-5094	5	_	_	
38-29	5094-5095	,	_	_	
38-30	5096-5097	6	_	_	
38-31	5097-5098	)	_	_	
38-32	5098-5099	.	_	_	

#Text=This is specific because neither Rad51 (lane 1), ubiquitin (lane 2), nor NEDD8 (lane 3) could modify RanGAP1.
39-1	5100-5104	This	_	_	
39-2	5105-5107	is	_	_	
39-3	5108-5116	specific	_	_	
39-4	5117-5124	because	_	_	
39-5	5125-5132	neither	_	_	
39-6	5133-5138	Rad51	_	_	
39-7	5139-5140	(	_	_	
39-8	5140-5144	lane	_	_	
39-9	5145-5146	1	_	_	
39-10	5146-5147	)	_	_	
39-11	5147-5148	,	_	_	
39-12	5149-5158	ubiquitin	_	_	
39-13	5159-5160	(	_	_	
39-14	5160-5164	lane	_	_	
39-15	5165-5166	2	_	_	
39-16	5166-5167	)	_	_	
39-17	5167-5168	,	_	_	
39-18	5169-5172	nor	_	_	
39-19	5173-5178	NEDD8	_	_	
39-20	5179-5180	(	_	_	
39-21	5180-5184	lane	_	_	
39-22	5185-5186	3	_	_	
39-23	5186-5187	)	_	_	
39-24	5188-5193	could	_	_	
39-25	5194-5200	modify	_	_	
39-26	5201-5208	RanGAP1	_	_	
39-27	5208-5209	.	_	_	

#Text=The purified RH-RanGAP1 derivatives were also detected in a separate Western blot analysis utilizing anti-RH monoclonal antibody (lanes 7 12).
40-1	5210-5213	The	_	_	
40-2	5214-5222	purified	_	_	
40-3	5223-5233	RH-RanGAP1	_	_	
40-4	5234-5245	derivatives	_	_	
40-5	5246-5250	were	_	_	
40-6	5251-5255	also	_	_	
40-7	5256-5264	detected	_	_	
40-8	5265-5267	in	_	_	
40-9	5268-5269	a	_	_	
40-10	5270-5278	separate	_	_	
40-11	5279-5286	Western	_	_	
40-12	5287-5291	blot	_	_	
40-13	5292-5300	analysis	_	_	
40-14	5301-5310	utilizing	_	_	
40-15	5311-5318	anti-RH	_	_	
40-16	5319-5329	monoclonal	_	_	
40-17	5330-5338	antibody	_	_	
40-18	5339-5340	(	_	_	
40-19	5340-5345	lanes	_	_	
40-20	5346-5347	7	_	_	
40-21	5348-5350	12	_	_	
40-22	5350-5351	)	_	_	
40-23	5351-5352	.	_	_	

#Text=As shown, both the unmodified RanGAP1 and sentrinized RanGAP1 were detected in all samples.
41-1	5353-5355	As	_	_	
41-2	5356-5361	shown	_	_	
41-3	5361-5362	,	_	_	
41-4	5363-5367	both	_	_	
41-5	5368-5371	the	_	_	
41-6	5372-5382	unmodified	_	_	
41-7	5383-5390	RanGAP1	_	_	
41-8	5391-5394	and	_	_	
41-9	5395-5406	sentrinized	_	_	
41-10	5407-5414	RanGAP1	_	_	
41-11	5415-5419	were	_	_	
41-12	5420-5428	detected	_	_	
41-13	5429-5431	in	_	_	
41-14	5432-5435	all	_	_	
41-15	5436-5443	samples	_	_	
41-16	5443-5444	.	_	_	

#Text=It should be noted that p90 in lanes 7 9 was derived from RanGAP1 modified by native sentrin in COS cells.
42-1	5445-5447	It	_	_	
42-2	5448-5454	should	_	_	
42-3	5455-5457	be	_	_	
42-4	5458-5463	noted	_	_	
42-5	5464-5468	that	_	_	
42-6	5469-5472	p90	_	_	
42-7	5473-5475	in	_	_	
42-8	5476-5481	lanes	_	_	
42-9	5482-5483	7	_	_	
42-10	5484-5485	9	_	_	
42-11	5486-5489	was	_	_	
42-12	5490-5497	derived	_	_	
42-13	5498-5502	from	_	_	
42-14	5503-5510	RanGAP1	_	_	
42-15	5511-5519	modified	_	_	
42-16	5520-5522	by	_	_	
42-17	5523-5529	native	_	_	
42-18	5530-5537	sentrin	_	_	
42-19	5538-5540	in	_	_	
42-20	5541-5544	COS	_	_	
42-21	5545-5550	cells	_	_	
42-22	5550-5551	.	_	_	

#Text=This is further supported by the observation of a 90 kDa doublet in the HA-sentrin-1, 2, or 3 transfected sample (lanes 10 12).
43-1	5552-5556	This	_	_	
43-2	5557-5559	is	_	_	
43-3	5560-5567	further	_	_	
43-4	5568-5577	supported	_	_	
43-5	5578-5580	by	_	_	
43-6	5581-5584	the	_	_	
43-7	5585-5596	observation	_	_	
43-8	5597-5599	of	_	_	
43-9	5600-5601	a	_	_	
43-10	5602-5604	90	_	_	
43-11	5605-5608	kDa	_	_	
43-12	5609-5616	doublet	_	_	
43-13	5617-5619	in	_	_	
43-14	5620-5623	the	_	_	
43-15	5624-5634	HA-sentrin	_	_	
43-16	5634-5635	-	_	_	
43-17	5635-5636	1	_	_	
43-18	5636-5637	,	_	_	
43-19	5638-5639	2	_	_	
43-20	5639-5640	,	_	_	
43-21	5641-5643	or	_	_	
43-22	5644-5645	3	_	_	
43-23	5646-5657	transfected	_	_	
43-24	5658-5664	sample	_	_	
43-25	5665-5666	(	_	_	
43-26	5666-5671	lanes	_	_	
43-27	5672-5674	10	_	_	
43-28	5675-5677	12	_	_	
43-29	5677-5678	)	_	_	
43-30	5678-5679	.	_	_	

#Text=The upper band of the doublet is most likely RanGAP1 modified by HA-sentrin and the lower band is most likely RanGAP1 modified by native sentrin (lanes 10 12).
44-1	5680-5683	The	_	_	
44-2	5684-5689	upper	_	_	
44-3	5690-5694	band	_	_	
44-4	5695-5697	of	_	_	
44-5	5698-5701	the	_	_	
44-6	5702-5709	doublet	_	_	
44-7	5710-5712	is	_	_	
44-8	5713-5717	most	_	_	
44-9	5718-5724	likely	_	_	
44-10	5725-5732	RanGAP1	_	_	
44-11	5733-5741	modified	_	_	
44-12	5742-5744	by	_	_	
44-13	5745-5755	HA-sentrin	_	_	
44-14	5756-5759	and	_	_	
44-15	5760-5763	the	_	_	
44-16	5764-5769	lower	_	_	
44-17	5770-5774	band	_	_	
44-18	5775-5777	is	_	_	
44-19	5778-5782	most	_	_	
44-20	5783-5789	likely	_	_	
44-21	5790-5797	RanGAP1	_	_	
44-22	5798-5806	modified	_	_	
44-23	5807-5809	by	_	_	
44-24	5810-5816	native	_	_	
44-25	5817-5824	sentrin	_	_	
44-26	5825-5826	(	_	_	
44-27	5826-5831	lanes	_	_	
44-28	5832-5834	10	_	_	
44-29	5835-5837	12	_	_	
44-30	5837-5838	)	_	_	
44-31	5838-5839	.	_	_	

#Text=It should be noted that a single 90 kDa band was observed in cells expressing HA-tagged sentrin-1 (lane 4 6), suggesting that RanGAP1 is modified by one sentrin-1 molecule.
45-1	5840-5842	It	_	_	
45-2	5843-5849	should	_	_	
45-3	5850-5852	be	_	_	
45-4	5853-5858	noted	_	_	
45-5	5859-5863	that	_	_	
45-6	5864-5865	a	_	_	
45-7	5866-5872	single	_	_	
45-8	5873-5875	90	_	_	
45-9	5876-5879	kDa	_	_	
45-10	5880-5884	band	_	_	
45-11	5885-5888	was	_	_	
45-12	5889-5897	observed	_	_	
45-13	5898-5900	in	_	_	
45-14	5901-5906	cells	_	_	
45-15	5907-5917	expressing	_	_	
45-16	5918-5927	HA-tagged	_	_	
45-17	5928-5935	sentrin	_	_	
45-18	5935-5936	-	_	_	
45-19	5936-5937	1	_	_	
45-20	5938-5939	(	_	_	
45-21	5939-5943	lane	_	_	
45-22	5944-5945	4	_	_	
45-23	5946-5947	6	_	_	
45-24	5947-5948	)	_	_	
45-25	5948-5949	,	_	_	
45-26	5950-5960	suggesting	_	_	
45-27	5961-5965	that	_	_	
45-28	5966-5973	RanGAP1	_	_	
45-29	5974-5976	is	_	_	
45-30	5977-5985	modified	_	_	
45-31	5986-5988	by	_	_	
45-32	5989-5992	one	_	_	
45-33	5993-6000	sentrin	_	_	
45-34	6000-6001	-	_	_	
45-35	6001-6002	1	_	_	
45-36	6003-6011	molecule	_	_	
45-37	6011-6012	.	_	_	

#Text=These studies also provide the first evidence that RanGAP1 could be covalently modified by all sentrin family members.
46-1	6013-6018	These	_	_	
46-2	6019-6026	studies	_	_	
46-3	6027-6031	also	_	_	
46-4	6032-6039	provide	_	_	
46-5	6040-6043	the	_	_	
46-6	6044-6049	first	_	_	
46-7	6050-6058	evidence	_	_	
46-8	6059-6063	that	_	_	
46-9	6064-6071	RanGAP1	_	_	
46-10	6072-6077	could	_	_	
46-11	6078-6080	be	_	_	
46-12	6081-6091	covalently	_	_	
46-13	6092-6100	modified	_	_	
46-14	6101-6103	by	_	_	
46-15	6104-6107	all	_	_	
46-16	6108-6115	sentrin	_	_	
46-17	6116-6122	family	_	_	
46-18	6123-6130	members	_	_	
46-19	6130-6131	.	_	_	

#Text=This modification is highly specific because neither NEDD8 nor ubiquitin could form a covalent linkage with RanGAP1.
47-1	6132-6136	This	_	_	
47-2	6137-6149	modification	_	_	
47-3	6150-6152	is	_	_	
47-4	6153-6159	highly	_	_	
47-5	6160-6168	specific	_	_	
47-6	6169-6176	because	_	_	
47-7	6177-6184	neither	_	_	
47-8	6185-6190	NEDD8	_	_	
47-9	6191-6194	nor	_	_	
47-10	6195-6204	ubiquitin	_	_	
47-11	6205-6210	could	_	_	
47-12	6211-6215	form	_	_	
47-13	6216-6217	a	_	_	
47-14	6218-6226	covalent	_	_	
47-15	6227-6234	linkage	_	_	
47-16	6235-6239	with	_	_	
47-17	6240-6247	RanGAP1	_	_	
47-18	6247-6248	.	_	_	
